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Abstract  
BACKGROUND: Prostatic carcinoma (PCa) deriv es f rom prostatic epithelial cells. Howev er stromal 
microenv ironment, associated with malignant epithelium, also play s a role in prostatic carcinogenesis. Alterations 
in prostatic stromal cells contribute to the loss of growth control in epithelial cells that lead to progression of  PCa. 
AI M: To analy se the diff erences between Androgen Receptor (AR) expression in both epithelial and stromal cells 
in PCa and the surrounding benign prostatic hy perplasia (BPH) and to compare the results with tumour grade. 
MATERI AL AND METHODS: Samples f rom 70 cases of  radical prostatectomy  specimens were used. The 
expression and intensity  of the signal f or AR was analy sed in the epithelial and stromal cells of PCa and BPH, and 
the data was quantif ied using histological score (H-score). 
RESULTS: AR showed signif icantly  lower expression in both epithelial and stromal cells of  PCa compared to 
BPH. In PCa a signif icant positiv e correlation of  AR expression was f ound between stromal and epithelial cells of  
PCa. AR expression showed a correlation between the stromal cells of  PCa and tumour grade. 
CONCLUSION: AR expression is reduced in epithelial and stromal cells of  PCa. Expression of AR in stromal cells 
of PCa signif icantly correlates with tumour grade. 
 
 
 
 
 
 
 
 
Introduction 
 
Prostatic carcinoma (PCa) is the most 
frequently diagnosed malignancy and the second 
leading cause of cancer-related death in men in 
industrialized countries [1]. Androgens play a vital role 
in growth, differentiation and maintenance of prostate 
tissue via Androgen Receptor (AR). AR in stromal 
cells contributes to the development and growth of 
prostate during fetal stages as well as during prostate 
carcinogenesis and cancer progression [1]. 
Researchers have mainly focused on studying 
epithelial AR expression whereas there is limited data 
concerning stromal AR expression.  
AR expression represents a potential 
prognostic marker for prostatic carcinoma, but more 
studies are needed in order to prove the usefulness of 
this factor in the future.  
 
Materials and Methods 
 
We reviewed 70 patients who underwent 
radical prostatectomy for prostatic carcinoma in the 
Pathology Laboratory in Clinical Hospital Acibadem – 
Sistina, Skopje, Macedonia between January 2010 
and July 2015. All cases presented with localized 
disease without the lymph node metastatic 
involvement and all cases were assigned to acinar 
types of prostatic adenocarcinoma. Representative 
samples were chosen from the periphery of PCa that 
contained relatively equal amounts of tumour and 
surrounding benign prostatic hyperplasia (BPH).  
The immunohistochemical analysis was 
performed using Androgen Receptor (AR) mouse 
antibody clone AR441 (DAKO) isotype IgG1 kappa 
dilution 1:50. For visualization of the antigen-antibody 
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complex DAKO REALTM En VisionTM Detection 
System. Peroxidase/DAB+, Rabbit/Mouse was used.  
To achieve a relevant analysis of the 
immunostaining, we analysed the positive signal and 
the intensity of the signal. We found the positive 
nuclear signal in stromal and epithelial cells of 
prostatic carcinoma and normal prostate tissue. The 
signal was detected on small magnification (x 40) in 
order to find an area with the most intense signal in 
the first step. Then on large magnification (x 400), we 
counted at least 100 epithelial and stromal cells. The 
number of positive nuclei was shown as a percentage 
of the total number of counted nuclei. The intensity of 
the signal was graded on a scale from 0 to 3 where 
the 0=no signal, 1= weak signal, 2=moderate signal 
and 3=strong signal. Additionally a histological score 
(H-score) was constructed that measures the intensity 
and distribution of the signal using the formula: [3 
(strong signal) x (percentage of cells with strong 
signal)] + [2 (moderate signal) x  (percentage of cells 
with moderate signal)] + [1 (weak signal) x 
(percentage of cells with weak signal)]. The 
histological score ranges from 0 to 300 [2, 3]. The 
data were compared between stromal and epithelial 
cells in PCa and the surrounding BPH.  
Additionally, the data were compared with 
tumour grade using the Gleason score retrieved from 
the medical records. Gleason score was grouped in 
Gleason prognostic grade groups as follows: Gleason 
prognostic grade group 1 – Gleason sum 1-6; 
Gleason prognostic grade group 2 – Gleason score 
3+4; Gleason prognostic grade group 3 – Gleason 
score 4+3; Gleason prognostic grade group 4 – 
Gleason score 4+4 and Gleason prognostic grade 
group 5 – Gleason sum 9-10.  
For statistical analyses of the data the 
following methods were used: descriptive methods 
(average, median), methods of testing significance of 
differences among analyzed parameters (Chi-square 
test, Student t test, Wilcoxon matched test, Analysis of 
Variance, Kruskal-Wallis ANOVA) and methods of 
determining correlation among designated parameters 
(Spearman coefficient of rang correlation and Pearson 
coefficient  of correlation). Statistically significant 
values were determined to be p < 0.05 and highly 
statistically significant values were determined to be p 
< 0.01. 
 
 
Results 
 
AR immunoreactivity was exclusively nuclear 
and was detected in tumour epithelial cells, epithelial 
cells of benign glands, peritumoral stromal cells and 
intraglandular stroma in BPH (Fig.1A and Fig. 1B). 
Tables 1 shows the mean values, average 
values as well as minimal and maximal values of AR 
expression in epithelial and stromal cells of prostatic 
carcinoma and the surrounding BPH.  
A)  
B)  
C)  
Figure 1: A) Expression of Androgen Receptor in epithelial and 
stromal cells in prostatic carcinoma (Androgen Receptor x 400); B) 
Expression of Androgen Receptor in epithelial and stromal cells in 
benign prostatic tissue (Androgen Receptor x 400); C) 
Heterogenous signal in epithelial cells of prostatic carcinoma in 
poorly differentiated tumors (Androgen Receptor x 600) 
 
The expression of AR in the epithelial cells of 
PCa is significantly (Wilcoxon Matched Pairs Z = 3.1 p 
= 0.002) lower compared to the expression of AR in 
BPH (med 257.5 vs. 267). We registered significantly 
lower (t = 9.5 p < 0.001) average values of AR 
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expression in PCa compared to BPH (114.5 vs. 161) 
in the stromal cells. The average value of AR 
expression in the epithelial cells of PCa is 253.73 ± 
22.9 and is significantly higher than the average value 
of AR expression in stromal cells of PCa with a score 
of 114.2 ± 37.3 (t = 34.7, p < 0.01). The value of AR 
expression in the epithelial cells of BPH is significantly 
(Wilcoxon Matched Pairs Z = 7.3 p < 0.01) higher than 
the expression of AR in stromal cells of BPH (med 
267 vs. 161).  
Table 1: Androgen Receptor (AR) expression using histological 
score (H-SCORE) in the epithelial and stromal cells in prostatic 
carcinoma and benign prostatic tissue 
 N 
Descriptive statistics – AR (H-SCORE) 
mean ± SD  median min - max 
Carcinoma – epithelial cells 70 253.73 ± 22.9 257.5 (246 – 272) 153 - 285 
Carcinoma – stromal cells 70 114.2 ± 37.3 114.5 (90 – 142)  37 – 208 
Benign prostatic tissue – epithelial cells 70 264.14 ± 16.4 267 (260 – 275)  185 – 286 
Benign prostatic tissue – s tromal cells  70 161.61 ± 22.1 161 (148 – 177)  110 – 212 
 
These data show that there was a drop in AR 
expression in both stromal and epithelial cells in 
prostatic carcinoma compartment but the drop of AR 
expression was more pronounced in the stromal 
compartment of prostatic carcinoma.  
We studied the correlation of AR expression 
between the epithelial and stromal cells of PCa and 
BPH. The value of Pearson coefficient of linear 
correlation shows that expression of AR in the stromal 
cells of PCa significantly positively correlates with AR 
expression in the epithelial cells of PCa (r  = 0.046 p < 
0.01). The correlation between AR expression in the 
epithelial and stromal cells of BPH is positive but 
statistically not significant (r = 0.22 p > 0.05). A 
positive but not significant correlation exists between 
AR expression in epithelial cells of PCa and epithelial 
cells of BPH (R = 0.056, p = 0.6). Also, AR expression 
between stromal cells of PCa and BPH shows positive 
but not significant correlation (R = 0.094, p = 0.44). 
The analyses of PCa in relation to tumor 
grade (Gleason score) according to the new Gleason 
score grouping showed that 12 cases belonged to 
Gleason prognostic grade group 1 (Gleason sum 2-6), 
23 cases belonged to Gleason prognostic grade group 
2 (Gleason score 3+4), 24 cases belonged to Gleason 
prognostic grade group 3 (Gleason score 4+3), 3 
cases belonged to Gleason prognostic grade group 4 
(Gleason score 4+4), and 8 cases belonged to 
Gleason prognostic grade group 5 (Gleason sum 9-
10) (Table 2).  
Table 2: Distribution of patients compared to Gleason 
prognostic grade group 
Gleason pr ognostic grade group N = 70 (%) 
1 12 (17.14) 
2 23 (32.86) 
3 24 (34.29) 
4 3 (4.29)  
5 8 (11.43)  
There was no significant  statistical difference 
in the average values of AR expression and Gleason 
prognostic grade group (F = 0.25,  p = 0.9) in the 
epithelial cells of PCa (Table 3). 
Table 3: Expression of Androgen Receptor (AR) in epithelial 
cells of prostatic carcinoma compared to Gleason prognostic 
grade group 
Gleason grade 
group 
N Descriptive statistics – AR expression in epithelial cells of 
prostatic carcinoma 
mean ± SD  minimum - maximum 
1 12 255.17 ± 37.1 153 – 285 
2 23 251.87 ± 21.2 191 – 282 
3 24 256.79 ± 12.9 228 – 277 
4 3 251.33 ± 20.5 234 – 274 
5 8 248.62 ± 29.2 212 – 280 
Tested differences  Anal ysis of Variance F = 0.25, p = 0.9 
 
The average value of AR expression in the 
stroma of PCa showed a statistically significant 
difference compared to Gleason grade group (F = 
4.33, p = 0.0036). In the Gleason prognostic grade 
group 1 the average value was 144.0 ± 41 that was 
significantly higher compared to Gleason prognostic 
grade groups 3, 4 and 5 (p = 0.033; p = 0.0034; p = 
0.0085 consecutively) (Table 4).  
Table 4: Expression of Androgen Receptor (AR) in stromal 
cells of prostatic carcinoma compared to Gleason prognostic 
grade group 
Gleason grade group N Descriptive statistics – AR expression in stromal cells of 
prostatic carcinoma 
mean ± SD  minimum - maximum 
1 12 144.0 ± 41.9 42 – 208 
2 23 117.87 ± 34.4 50 – 167 
3 24 108.17 ± 30.3 48 – 178 
4 3 79.0 ± 36.5 37 – 103 
5 8 90.25 ± 30.4 51 – 137 
Tested differences  Anal ysis of Variance F=4.33 p=0.0036**; Post hoc Tur key 
test; Gleason grade group 1 vs . Gleason grade group 3 
p=0.033*; Gleason grade group 1 vs. Gl eason grade group 4 
p=0.0034**; Gleason grade group 1 vs . Gleason grade group 
3 p=0.0085**  
*p < 0.05;  **p<0.01.  
 
We also analysed the correlation between 
Gleason grade group and AR in both the epithelial 
and stromal compartments of PCa. Tumor 
differentiation expressed through Gleason score did 
not show significant correlation with AR expression in 
the epithelial cells of PCa (R = -0.15, p = 0.02). The 
correlation between Gleason score and AR 
expression in the stromal cells of PCa was negative 
and statistically significant (R = -0.44.  p < 0.01) which 
means that as a tumour showed less differentiation 
AR expression in the stromal cells of prostatic 
carcinoma decreased significantly and vice versa.  
 
 
Discussion 
 
The role of stroma in prostate development, 
prostate function and the maintenance of tissue 
differentiation is well established [1]. Androgen 
Receptor (AR) plays a critical role in prostatic 
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development through regulation of androgen effects 
on epithelial cells. AR expression is mainly localized in 
the mesenchymal tissue in the fetal period while AR is 
mainly localized in epithelial compartment in the post-
natal period [1]. The mesenchymal AR initiates and 
controls proliferation and differentiation of epithelial 
cells while epithelial AR plays a role in functioning and 
differentiation of the prostatic gland hence stromal -
epithelial interactions are reciprocal in the 
development of mature prostatic tissue [1]. 
AR in epithelial cells of prostatic carcinoma 
was studied by several authors [3-18]. Some authors 
found greater expression of AR in epithelial cells in 
well-differentiated tumours compared to moderately 
and poorly differentiated tumours [4-8]. In our study 
also, there was a slightly greater expression of AR in 
epithelial cells in better-differentiated tumours but the 
difference was statistically not significant (F = 0.25, p 
= 0.9). In some prospective studies, authors 
presented higher expression of AR to be associated 
with better prognosis [4, 5, 9] while other authors 
suggested higher AR expression in the epithelial  cell 
to be associated with worse prognosis [10-13]. 
However, most authors agree that a phenomenon 
known as AR expression heterogeneity was a 
consistent finding in poorly differentiated tumours [4, 
8, 9, 14, 15]. This phenomenon was also observed in 
our study in poorly differentiated carcinomas (Fig. 1C).  
The discrepancies in these findings can be 
attributed to several factors. First of all, the lack of 
unified criteria about the method used in the analyses 
could be an important factor. Second the specimens 
can also attribute to these varied results since some 
authors performed their analyses on biopsy 
specimens [4, 5, 9, 14], some of transurethral 
resection specimens [5, 6, 16, 17] and most of them 
on radical prostatectomy specimens [3, 7, 8, 10-
13,18]. At the end AR expression heterogeneity 
complicates the matter further since the selection of 
analysed area is compromised. In order to eliminate 
any possible miss assessments, we used only radical 
prostatectomy specimens and selected the area of 
analysis where the staining signal was strongest, and 
also we used the H-score to incorporate both the 
staining intensity and percentage of stained cells as it 
is specified in the section of Material and Methods. 
With this approach, we tried to address these issues 
concerning the inconsistencies in previous 
assessments of AR expression. Concerning the issue 
of the method used to assess AR expression, we 
used H-score as was recommended by some authors 
as a most valid method of AR expression analysis [3]. 
The second issue concerning material used to assess 
AR expression we only  used radical prostatectomy 
specimens as they contain a lot of material to choose 
adequate samples for analysis. In the end, the 
problem of heterogeneity was address by choosing 
areas of highest staining intensity and performing the 
analyses in the chosen areas as was recommended 
by some authors [3].  
Stromal expression of AR was much less 
studied than an epithelial expression of AR in PCa [1, 
19]. Authors found a decline in stromal AR expression 
in the stromal cells surrounding prostatic cancer. Also, 
the drop of expression was higher in poorly 
differentiated carcinomas. Authors found a statistically 
significant decrease of stromal AR expression in 
carcinomas compared to stromal AR expression in the 
benign prostatic hyperplasia surrounding the prostatic 
carcinoma [1]. These findings are consistent with our 
data. In our study, the decrease in AR expression in 
the stromal cells in poorly differentiated carcinomas 
showed statistical significance. There was a negative 
statistically significant correlation of AR expression 
compared to Gleason grade group meaning that AR 
expression was significantly higher in well-
differentiated carcinomas compared to poorly 
differentiated carcinomas.  
AR expression belongs to the category of 
prognostic factors of prostatic carcinoma [20, 21]. 
There are three categories of prognostic factors. The 
first group encompasses well established 
histopathological factors of prostatic carcinoma like 
the pathologic stage of the disease, status of surgical 
margins in radical prostatectomy specimens and 
Gleason grade. The second category is comprised of 
factors that are presumed to be established in the 
near future like histological types of prostatic 
carcinoma, tumour volume, and DNA ploidy. The third 
category belongs to factors that do not possess 
enough data that they may represent prognostic 
factors shortly. These factors are genetic markers, 
neuroendocrine markers, proli ferative markers, 
perineurial, vascular or lymphatic invasion, small 
vessel density, nuclear morphometry and AR 
expression of epithelial cells [20, 21]. For this third 
category of prognostic factors, authors are welcomed 
to perform studies in order to prove their clinical 
usefulness [20, 21].  
AR expression in epithelial cells of prostatic 
carcinoma has been studied more than AR expression 
in stromal cells. Our study shows the significance of 
AR expression assessment in both epithelial and 
stromal cells because both epithelial and stromal cells 
may contribute to initiation and progression of 
prostatic carcinoma. 
Further studies are needed in order to prove 
the clinical usefulness of this potential prognostic 
factor and correlations are needed with the already 
well established prognostic factors like the Gleason 
grade.  
In conclusion, our study shows a significant 
drop of AR expression in both epithelial and stomal 
cells of prostatic carcinoma compared to benign 
prostatic tissue that indicates that there is a 
quantitative change in AR expression in the malignant 
prostatic tissue. The drop in AR expression is more 
pronounced in the stromal cells. Also, this drop of AR 
expression continues as prostatic carcinomas evolve 
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from well differentiated to poorly differentiated 
carcinomas. The drop of AR expression in the 
epithelial cells, as they progress to poorly 
differentiated carcinomas, is not statistically significant 
but the drop of AR expression in the stromal cells is 
statistically significant. This concludes that AR 
expression in stromal cells of prostatic carcinoma 
could represent one of the prognostic factors for 
prostatic carcinoma in the future.  
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